Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)

NCT06219941 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06219941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06219941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Recruiting
Start date
December 13, 2023
Completion date
June 28, 2027
Enrollment
226 (estimated)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer, gastric cancer, gastroesophageal junction cancer, pancreatic ductal adenocarcinoma